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Congenital imprinting disorders (IDs) are characterised by molecular changes affecting imprinted chromosomal
regions and genes, i.e. genes that are expressed in a parent-of-origin specific manner. Recent years have seen a
great expansion in the range of alterations in regulation, dosage or DNA sequence shown to disturb imprinted
gene expression, and the correspondingly broad range of resultant clinical syndromes. At the same time, however,
it has become clear that this diversity of IDs has common underlying principles, not only in shared molecular
mechanisms, but also in interrelated clinical impacts upon growth, development and metabolism. Thus, detailed
and systematic analysis of IDs can not only identify unifying principles of molecular epigenetics in health and
disease, but also support personalisation of diagnosis and management for individual patients and families.
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Imprinting disorders (IDs) are a group of congenital dis-
eases characterised by overlapping clinical features af-
fecting growth, development and metabolism, and
common molecular disturbances, affecting genomically
imprinted chromosomal regions and genes. The term
genomic imprinting describes the expression of specific
genes in a parent-of-origin specific manner - i.e. they are
expressed only from the maternal or from the paternal
gene copy, but not biparentally. Disturbances of
imprinted genes may alter their regulation (“epigenetic
mutation") and dosage and rarely their genomic se-
quences can be altered (“genetic mutation”).
So far, more than 150 human genes have been shown
to be imprinted (for review, http://www.geneimprint.-
com/site/genes-by-species), but it is likely that more re-
main to be identified. Imprinting marks, like other
epigenetic marks, are re-established at each generation* Correspondence: teggermann@ukaachen.de
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cell lineages, and then in early zygotic development. The
critical difference between imprinting marks and all
others is that they elude postzygotic reprogramming,
and therefore are essentially ubiquitous and permanent
in somatic tissues - except for the germline lineage that
embarks upon the establishment of the subsequent gen-
eration (for review, [1]).
Imprinted loci often comprise multiple genes under
coordinated epigenetic control (Figs. 1, 2, 3, 4, 5, 6, 7, 8
and 9). This control includes four interacting molecular
components: DNA methylation, post-translational his-
tone modification, chromatin structure and non-coding
RNAs. The intricate interactions of these regulatory
mechanisms across development lead to a stage- and
tissue-specific transcriptional activity in cells with identi-
cal DNA sequences.
In IDs, the regulation of imprinted genes and imprint-
ing clusters are disturbed by different changes. In the
majority of ID patients only the disease-specific loci are
affected, but an increasing number of individuals have
been shown to have disturbed methylation at multiple
imprinted loci, the so-called multilocus methylation im-
printing disturbances (MLID). Another extreme examplerticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 PLAGL1 imprinted region on chromosome 6q24, altered in TNDM. The currently known imprinted loci associated with one of the known
IDs. (Filled boxes, protein coding genes; empty boxes, non-coding genes; Ω miRNAs; filled lollipops, methylated regions; empty lollipops,
unmethylated regions; black, genes with biparental expression; red, genes expressed from the maternal (mat) chromosome; blue, genes expressed
from the paternal (pat) chromosome; grey, silenced gene copies. Arrows above the genes, transcription direction of sense genes; arrows below
the genes, transcription direction of anti-sense genes. IC, imprinting control region)
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loidy (e.g. complete hydatidiform moles, where all the
chromosomes are of paternal origin) or triploidies (e.g.
partial hydatidiform moles where an extra haploid set of
chromosomes of either maternal or paternal origin is
present). These cases are not viable. However, mosaic
genomewide uniparental isodiploidy has been reported
to be compatible with life (for review, [2]).
Types of mutations and epimutations in IDs
In the majority of the well established IDs, the same four
classes of molecular changes have been reported (Table 1,
Figs. 1, 2, 3, 4, 5, 6, 7, 8 and 9): uniparental disomy
(UPD), chromosomal imbalances, aberrant methylation
(epimutation) and genomic mutations in imprinted
genes. The functional result in each case is the unbal-
anced expression of imprinted genes, but the phenotypic
outcome depends on the parental allele affected by the
mutation.Since the genetic counseling for each ID is affected by
both its familial inheritance and its underlying pathogen-
etic mechanism, precise molecular diagnosis is essential
for accurate management and reproductive counseling.
Furthermore, in some IDs somatic and germline mosai-
cism have been reported, a finding which may be diffi-
cult to diagnose, but must be considered since it may
compromise molecular genetic testing.
Uniparental Disomy (UPD)
UPD is the inheritance of both chromosomal homo-
logues from the same parent and has been reported for
nearly all IDs (Table 1; for review, [3]). The recurrence
risk for another child with UPD is generally low with the
exception of those UPDs affecting acrocentric chromo-
somes (chromosomes 14 and 15): these chromosomes
are prone to Robertsonian translocations (RT) which
predispose to non-disjunctional errors and thus a UPD
formation. However, the risk to have a child with UPD is
Fig. 2 The loci GRB10 in 7p12.1 and MEST in 7q32, affected by (segmental) upd(7)mat or chromosomal imbalances in SRS
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mended in carriers of balanced translocations affecting
chromosomes carrying imprinted genes [4].
Chromosomal rearrangements (deletions, duplications,
translocations)
Chromosomal imbalances either cause a loss of a gene
and thereby a loss of expression of an imprinted gene in
case of deletions or translocations or they result in an
overexpression by duplication of imprinted chromo-
somal material. However, due to the complex regulation
mechanisms in imprinted regions, loss of chromosomal
material can also indirectly cause an overexpression of
an imprinted gene due to the removal of a negative cis-
acting element and vice versa (e.g. [5–7]).
In some IDs, deletions account for the majority of
cases, e.g. in Angelman syndrome (AS) and Prader-
Willi syndrome (PWS). They can either occur de novo,
or they can be caused by inherited chromosomal rear-
rangements (e.g. RT). In case of familial cases, the
parent-of-origin-dependent gene expression results in
autosomal-dominant inheritance with a parent-of-
origin-dependant penetrance.Intragenic mutations in imprinted genes
So far, genomic point mutations in imprinted genes have
only been reported for Beckwith-Wiedemann syndrome
(BWS), Silver-Russell syndrome (SRS), AS, precocious
puberty and pseudohypoparathyoridism (PHP) (Table 1).
In precocious puberty syndrome (central precocious pu-
berty 2; cppb2), MKRN3 mutations are the only causa-
tive molecular alterations known so far. In the other
IDs, their significance differs: AS mutations in the
UBE3A contribute to 10–15 % of cases, and approxi-
mately 30 % are inherited. In PHP, mutations on the
coding maternal allele of GNAS are responsible for
70 % of type 1A disease (~50 % of total PHP), whereas,
deletions of genomic regulatory regions have been iden-
tified in 20–30 % of the 1B subtype (~8.5 % of total
PHP) [8]. In BWS, inhibiting CDKN1C mutations can
be detected, in SRS, only one case with an activating
CDKN1C mutation has been reported so far [9]. To fur-
ther determine the recurrence risk in the families of
these patients, familial segregation studies should be of-
fered to establish the maternal/paternal inheritance or
lack thereof, even when parents do not show obvious
clinical features.
Fig. 3 The 11p15.5 cluster can be divided in two functional domains whose imprinting is dependent on distinct imprinting control regions
(H19/IGF2: IG DMR and KCNQ1OT1: TSS DMR). Mainly hypomethylation of the KCNQ1OT1: TSS DMR is responsible for SRS
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Epimutations aberrant methylation of a differentially
methylated region (DMR) without alteration of the same
genomic DNA sequence account for up to 50 % of mo-
lecular changes in IDs (Table 1). To contribute to the
full clinical picture of an ID, hypo- or hypermethylation
should affect the disease-specific germ-line DMR (e.g.
the H19-DMR in 11p15), but in several IDs the methyla-
tion at further DMRs (e.g. IGF2-DMRs in 11p15) is
altered [10] and might influence the severity of an ID
(e.g. Kagami-Ogata syndrome/KOS14, [11]). Epimutation
can occur as a result of a DNA mutation in a cis- or
trans-acting factor (“secondary epimutation”), or as a
primary epimutation in the absence of any DNA se-
quence change (“primary epimutation”). Primary epimu-
tations often occur after fertilization and lead to somatic
mosaicism. It has been estimated that the rate of pri-
mary epimutations is 1 or 2 orders of magnitude greater
than somatic DNA mutations [12] and is associated with
assisted reproductive technology [13], in keeping with
environmental disturbances.
In terms of molecular mechanism, the four causes of
IDs can interact: chromosomal translocations can pre-
dispose to both imbalances and UPD, and deletions orpoint mutations in regulatory domains can affect the im-
printing status of a DMR [6, 10, 14]. It is noteworthy that
some molecular changes may occur postzygotically, result-
ing in a mosaic distribution. Mosaicism can obscure
genotype-phenotype correlation and is also associated
with somatic asymmetry; and discordant monozygotic
twinning, which can be regarded as an extreme expression
of epigenetic asymmetry, is a common feature in IDs (for
review, [15]). It may also render difficult the molecular
diagnosis if the analysed tissue is not or poorly epigeneti-
cally modified.
Clinical and molecular findings in Imprinting
Disorders
With the exception of the precocious puberty syndrome,
the clinical features of IDs are present at birth and in
early childhood. Indeed, some of them can be identified
prenatally. Each ID is characterised by specific clinical
features, and they have been regarded as separate en-
tities. However, the majority of IDs share clinical (and
molecular) characteristics (Tables 1 and 2), and in nearly
all of them growth, metabolism and/or development are
affected. Furthermore, they share several sequelae (e.g.
diabetes; Table 2). In several disorders, the symptoms
Fig. 4 Epimutations and mutations in 11p15.5 are also responsible for BWS
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are probably mis- and underdiagnosed.
Currently, nine IDs have been described, but there are
certainly more: In addition to the generally accepted
paediatric IDs and the specific precocious puberty entity,
there are three further molecular disturbances in discus-
sion to represent separate IDs (upd(6)mat, upd(16)mat,
upd(20)mat).
Transient neonatal diabetes mellitus type 1
Transient neonatal diabetes mellitus type type 1
(TNDM1) is characterised by intrauterine growth retard-
ation (IUGR) and hyperglycaemia in infancy. The dia-
betes mellitus typically develops in the first weeks of life
and resolves by the age of 18 months; however, it is
growing clear that individuals with TNDM are at risk of
relapse, in adolescence or early adulthood, with type 2
diabetes [16, 17]. Aside from these features, TNDM1 has
no major cardinal features; however, individuals may
have congenital abnormalities [18]. Macroglossia (large
tongue) affects just under half of infants with TNDM1,
and about one in five individuals may also have a minor
anomaly of the abdominal wall. Other congenitalproblems are rare and may be associated with MLID ra-
ther than TNDM per se. Approximately 10 % of individ-
uals with TNDM1 do not present with hyperglycaemia
at birth [19].
TNDM is associated with an overexpression of
PLAGL1/ZAC in 6q24 (Fig. 1), a maternally imprinted
gene. It encodes a zinc finger protein which binds DNA
and hence influences the expression of other genes (for
review, [20].
Silver-Russell syndrome
SRS is a clinically and molecularly heterogeneous growth
retardation syndrome. Apart from pre- and postnatal
growth failure, the major features include a relative
macrocephaly at birth, a typical facial gestalt (protruding
forehead, triangular face), body asymmetry, and feeding
difficulties in infancy. Furthermore, first follow-up data
indicate a risk for adult-onset diseases [21]. The clinical
presentation is variable and at least in part influenced by
the mosaic distribution of molecular changes [22], but
several scoring systems have been suggested [23]. Ap-
proximately 10 % of SRS patients have maternal UPD
for chromosome 7 (upd(7)mat) or segmental upd(7q)mat
Fig. 5 The imprinted region in 14q32.2, and changes associated with TS14
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carry molecular changes in 11p15, the most prevalent
(~40 %) being hypomethylation of H19/IGF2: IG DMR
(Fig. 3). Additionally, numerous (submicroscopic) distur-
bances of chromosomes 7 and 11 as well as of other
chromosomes have been described; thus screening for
cryptic genomic imbalances is indicated after exclusion
of upd(7)mat and 11p15 epimutations [26, 27]. The
genes causing the SRS phenotype on chromosomes 7
and 11 are currently unknown, but evidences for a role
of IGF2 and CDKN1C in 11p15.5 and MEST in 7q32
have been reported [9, 28–30].
Beckwith-Wiedemann syndrome
BWS was initially called EMG syndrome from its three
main features of exomphalos, macroglossia and (neo-
natal) gigantism. The clinical diagnosis of BWS is often
difficult due to its variable presentation and the pheno-
typic overlap with other overgrowth syndromes (for re-
view, [31–33]) and isolated hemihypertrophy. In 5–7 %
of children, embryonal tumours (most commonly Wilms
tumour) are diagnosed.
In nearly 80 % of BWS patients chromosome 11p15.5
epimutations or mutations (Fig. 4), involving multipleloci, can be detected (including the ICR1 and
KCNQ1OT1: TSS DMR DMRs)(for review, [34]). Most
BWS cases are sporadic but familial inheritance is ob-
served in up to 15 % of all cases. Microdeletions/dupli-
cations or point mutations at the ICRs are usually found
in familial BWS with aberrant 11p15 methylation; for ex-
ample, deletions and point mutations of OCT4/SOX4
binding sites in H19/IGF2: IG DMR are associated with
H19/IGF2: IG DMR hypermethylation [5, 35, 36]. Con-
versely, CDKN1C mutations are frequent in familial
cases with normal 11p15 methylation [37]. These BWS
pedigrees resemble that of an autosomal dominant in-
heritance but with parent-of-origin dependent effects on
penetrance. Most cases of BWS with an KCNQ1OT1:
TSS DMR epimutation are sporadic but there is an asso-
ciation with assisted reproductive technologies [38]. Ro-
bust genotype/epigenotype-phenotype correlations have
been established for BWS [35, 39, 40]: hemihypertrophy
is strongly associated with upd(11)pat, exomphalos with
KCNQ1OT1: TSS DMR hypomethylation and CDKN1C
mutations, and, most importantly, the risk of Wilms
tumour is significantly increased in H19/IGF2: IG DMR
hypermethylation and upd(11)pat in comparison to the
other molecular subgroups. By contrast, other embryonic
Fig. 6 Molecular changes currently known to be associated with KOS14
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observed in patients with KCNQ1OT1: TSS DMR or
upd(11)pat but at a much lower incidence. Hence, the de-
termination of the molecular subtype is important for an
individual prognosis and management. Nevertheless, the
phenotypic transitions are fluid and testing for all molecu-
lar subtypes should be offered in patients with BWS
features.
Temple syndrome
Temple syndrome (TS14) was first described in 1991 in
a patient with a maternal UPD of chromosome 14 [41],
and after it turned out that it is a recognizable pheno-
type the name upd(14)mat syndrome was suggested.
Meanwhile, other molecular changes have been reported
as well [42, 43]; therefore, the name TS14 has been pro-
posed [44] (Fig. 5). TS14 is mainly characterised by pre-
natal and postnatal growth retardation, muscular
hypotonia, feeding difficulties in early childhood, truncal
obesity and early onset of puberty. TS14 patients show
clinical features overlapping with PWS and SRS; thus,
screening for chromosome 14q32 should be performed
in patients with PWS- and SRS-like phenotypes afterexclusion of the specific (epi)mutations. For TS14 the
role of an altered RTL1 and DLK1 expression has been
suggested [42].
Kagami-Ogata syndrome
The second recently defined ID is KOS14 which is
mainly characterised by polyhydramnios, placentome-
galy, excessive birth weight, a unique facial appearance
with full cheeks and protruding philtrum, distinctive
chest roentgenograms with coathanger rips and a bell-
shaped thorax, abdominal wall defects (omphalocele,
diastasis recti), variable developmental delay and/or in-
tellectual disability, poor sucking usually requiring gas-
tric tube feeding, hepatoblastoma and a mortality rate of
20–25 % in the neonate period [45].
Known causes of KOS are upd(14)pat (~65 %), epimu-
tations affecting the MEG3/DLK: IG DMR and the
MEG3: TSS DMR (~15 %) and microdeletions involving
the MEG3/DLK: IG DMR and/or the MEG3: TSS DMR
(~20 %) (Fig. 6). The detailed characterisation of KOS14
with deletions of different sizes has allowed the deci-
phering of the regulation mechanism in the 14q32
imprinted region [11, 46]: whereas deletion of the
Fig. 7 The imprinted region in 15q11.2 and PWS. UBE3A encodes an E3 ubiquitin-protein ligase which is expressed exclusively from the maternal
allele in human fetal brain and in adult frontal cortex. The role of ATP10A is unclear
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KOS14 phenotype and placental abnormalities, carriers
of deletions restricted to the MEG3: TSS DMR do not
show placental abnormalities. It has been postulated that
the increased expression of RTL1 is responsible for the
clinical outcome, whereas a role of DLK1 can be
neglected [42].
Angelman syndrome
A clinical diagnosis of AS demands fulfilment of four
major criteria and minimum three of the six minor cri-
teria. The major criteria are severe developmental delay,
movement or balance disorder, severe limitations in
speech and language and typical abnormal behavior in-
cluding happy demeanor and excessive laughter. The six
minor criteria are postnatal microcephaly, seizures, ab-
normal EEG, sleep disturbance, attraction to or fascin-
ation with water, and drooling [47]. The unique clinical
features do not usually manifest within the first year of
life, but developmental delay is noticed around 6 months
of age. In about 10 % of the individuals with a clinical
diagnosis of AS it is not possible to find the underlying
genetic mechanism and other diagnoses should beconsidered. AS can be caused by maternally derived de
novo deletion of 15q11-q13 (70–75 %), paternal unipa-
rental disomy (upd(15)pat) of chromosome 15 (3–7 %)
or an imprinting defect (2–3 %) all of which lead to lack
of expression of maternally expressed 15q11-q13 genes
(Fig. 7). Furthermore, mutations in UBE3A also cause
Angelman syndrome (10–15 %). Imprinting defects can
either be due to primary imprinting epimutations with-
out DNA sequence alterations or due to deletions in the
imprinting centre (IC) critical region (AS-SRO) [48, 49].
The 15q11-q13 chromosomal region contains imprinted
genes, some of which are exclusively expressed from ei-
ther of the parental alleles. Two exclusively maternally
expressed genes, UBE3A and ATP10A, are located with
this region: UBE3A encodes an E3 ubiquitin-protein lig-
ase which is expressed exclusively from the maternal al-
lele in human foetal brain and in adult frontal cortex
[50, 51]. AS can be caused either by lack of UBE3A ex-
pression or by mutations in UBE3A. The role of the
other imprinted gene, ATP10A, is however unclear. In
individuals with deletions, UPD or imprinting defects,
ATP10A expression is lacking, but in individuals with
point mutations in UBE3A it is left unaffected.
Fig. 8 Alterations in 15q11.2 in AS
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PWS is clinically characterised by severe hypotonia and
feeding difficulties in early infancy, followed by excessive
eating and development of morbid obesity in later in-
fancy or early childhood. Cognitive impairment is seen
in almost all individuals but varies in severity. A behav-
ioral phenotype with temper tantrums, stubbornness,
manipulative behavior and obsessive-compulsive dis-
order is constant. Hypogonadism in both males and fe-
males may cause genital hypoplasia and incomplete
pubertal development; and most individuals are infertile.
Short stature, and small hands and feet are common fea-
tures. Characteristic facial features, strabismus and scoli-
osis are often present. Clinical diagnostic criteria for
PWS have been developed [52, 53]; however, confirm-
ation of the clinical diagnosis with molecular genetic
testing is required.
PWS is caused by lack of expression of the paternally
contributed 15q11-q13 genes. There are three mecha-
nisms leading to PWS: deletion of the 15q11-q13
imprinted loci on the paternal allele (75–80 %), maternal
UPD of chromosome 15 (upd(15)mat) (20–25 %) and
imprinting defects (<1 %) (Fig. 8). The common break-
point for the deletions are the same as for AS. Imprint-
ing defects can either be due to primary epimutationswithout DNA sequence alterations or it can be due to
small deletions in the imprinting centre (IC) critical region
(PWS-SRO) [54]. The 15q11-q13 chromosomal region
contains imprinted genes, some of which are exclusively
expressed from either of the parental alleles. Paternally
expressed genes are: MKRN3, MAGEL2, NDN, PWRN1,
C15orf2, SNURF-SNRPN and several snoRNA genes
(SNORD64, SNORD107, SNORD108, SNORD109A,
SNORD109B, SNORD115 and SNORD116). SNORD115
and SNORD116 are present in 47 and 24 gene copies, re-
spectively, whilst the other snoRNA genes are single copy
genes. Deficiency of SNORD116 is thought to cause the
key characteristics of the PWS phenotype [55, 56].
Precocious puberty
Puberty is a complex biological process involving sexual
maturation and accelerated growth. These processes nor-
mally initiate when pulsatile secretion of gonadotropin-
releasing hormone (GnRH) from the hypothalamus begins.
Early activation of the hypothalamic-pituitary-gonadal axis
results in gonadotropin-dependent precocious puberty
(also known as central precocious puberty, CPP; develop-
ment of secondary characteristics before the age of 8 year
in girls and 9 years in boys). With the advent of advanced
sequencing methods, exome-sequencing of familial cases
Fig. 9 Organization and imprinting of the complex GNAS locus at 20q13.22, causing PHP
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with no previous link to hypothalamic-pituitary-gonadal
regulation. Loss-of-function mutations in the Makorin
ring finger 3 (MKRN3) were initially identified in CPP
families [57–60]. Consistent with the genes imprinting sta-
tus the phenotype was only present upon paternal trans-
mission of the mutation. Subsequently, mutations in
MKRN3 have been shown to be the most frequent cause
of familial CPP and they have also been detected in nearly
4 % in a cohort of 215 non-familial idiopathic CCP [61].
The MKRN3 gene (also known as ZNF127) is an intron-
less transcript located on chromosome 15q11.2 in the
PWS critical region, encoding for a protein with C3H
zinc-finger and RING zinc-finger motifs. Unlike other im-
printing disorders that can result from multiple mecha-
nisms, it is currently unknown if CCP can arise from loss
ofMKRN3 expression due to deletion, segmental maternal
uniparental disomy or an imprinting defect.
Pseudohypoparathyroidism
PHP is a group of disorders characterised by PTH resist-
ance in the kidney, i.e. pseudohypoparathyroidism. Most
cases of PHP belong to the type 1, i.e. are caused by gen-
etic or epigenetic alterations at the imprinted GNASlocus. PHP1A comprises patients affected with resistance
to PTH and TSH (and other GPCR proteins), and features
of obesity and Albright hereditary osteodystrophy includ-
ing short stature, brachydactyly, ectopic ossifications and
mental retardation. PHP1A is caused by inactivating muta-
tions in the maternal allele of the GNAS gene. Paternal
GNAS mutations are associated with AHO, no hormonal
resistance and no obesity, a constellation of features
grouped under the term of pseudopseudohypoparathyroid-
ism (PPHP) as well as with progressive osseous heteropla-
sia (POH). In contrast, the phenotype of most PHP1B
patients is limited to renal PTH resistance [62] and in
some cases, mild TSH resistance. Few patients with PHP1B
display some features of Albright hereditary osteodystro-
phy [63]. Patients with PHP1B share a loss of methylation
at the A/B differentially methylated region (DMR) of
GNAS, likely leading to the downregulated expression of
the GNAS-Gsα transcript in imprinted tissues (Fig. 9).
Some patients carry additional epigenomic changes along
the GNAS locus. About 20 % of PHP1B are inherited and
due to deletions of GNAS imprinting control regions. The
remaining 80 % are sporadic. A small subset is due to pa-
ternal UPD of chromosome 20q, yet the vast majority are
still of unknown cause (for review: [64]). Whilst obesity
Table 1 Overview on the molecular findings in the currently known IDs and their clinical characteristics
Imprinting disorder Prevalence OMIM Chromosomes/
imprinted regions
Type of mutation/epimutation and their
frequencies
MLID Mosaicism Recurrence risk Main clinical features
Transient Neonatal
Diabetes Mellitus (TNDM)
1/300.000 601410 6q24: PLAGL1: alt-TSS upd(6)pat 40 % <1 % IUGR, transient diabetes,
hyperglycemia without
ketoacidosis, macroglossia,
omphalocele
paternal duplications 40 % No Up to 50 %
methylation defects 20 % ~50 % Yes <1 %
Upd(6)mat Unknown Chromosome 6,
6q16.1qter
upd(6)mat Yes Unknown
Silver-Russell syndrome
(SRS; Russell-Silver
Syndrome, RSS)
1/75.000-
1/100.000
180860 7 upd(7)mat ~10 % 1
casea
No <1 % IUGR/PNGR, small prematurely
calcified placenta, rel. macrocephaly
at birth, hemihypotrophy, prominent
forehead, triangular face, feeding
difficulties
11p15: upd(11p15)mat single case Unknown Rare
Genome-wide uniparental
diploidy
single case Yes Rare
maternal duplication <1 % No Up to 50 %
H19/IGF2: IG DMR hypomethylation >38 %a 7-
10 %
Yes <1 %
CDKN1C point mutations 1 family reported No In familial cases: up
to 50 % in case of
maternal transmission
IGF2 point mutations 1 family reported No
Beckwith-Wiedemann
syndrome (BWS;
Wiedemann-Beckwith
syndrome, EMG)
1/15.000 130650 11p15: upd(11p15)pat ~20 % Yes <1 % Pre- and postnatal overgrowth,
organomegaly, macroglossia,
omphalocele, neonatal
hypoglycemia, hemihypertrophy,
increased tumour risk
Genome-wide uniparental
diploidy
~2 % Yes <1 %
chromosomal aberrations 2-4 % No Up to 50 %
IH19/IGF2:
IG DMR; KCNQ1OT1:
TSS-DMR
hypermethylation 5-10 % Yes unclear
hypomethylation 40-50 % 25 % Yes <1 %
CDKN1C point mutations 5 % (sporadic)
40–50 % (families)
No Up to 50 %
Kagami-Ogata syndrome
(KOS14; upd(14)pat
syndrome)
unknown 608149 14q32: upd(14)pat 65 % in case of RT IUGR, polyhydramnion, abdominal
and thoracal wall defects, bell-
shaped thorax, coat-hanger ribsMEG3/DLK1: IG DMR maternal deletion 15 % up to 50 %
MEG3: TSS DMR aberrant methylation 20 % <1 %
Temple syndrome (TS14;
upd(14)mat syndrome)
unknown 616222 14q32: upd(14)mat 78 % In case of RT IUGR/PNGR, neonatal hypotonia,
feeding difficulties in infancy, truncal
obesity, scoliosis, precocious puberty,
small feed and hands
MEG3/DLK1: IG DMR paternal deletion 10 % Up to 50 %
MEG3: TSS DMR aberrant methylation 12 % 1
casea
<1 %
Prader-Willi syndrome
(PWS)
1/25.000-
1/10.000
176270 15q11-q13 paternal deletion 70 % Up to 50 % PNGR, mental retardation, neonatal
hypotonia, hypogenitalism,
upd(15)mat <30 % In case of RT
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Table 1 Overview on the molecular findings in the currently known IDs and their clinical characteristics (Continued)
hypopigmentation, obesity/
hyperphagia
aberrant methylation ~1 % 1 case <1 %
Angelman syndrome
(AS)
1/20.000-
1/12.000
105830 15q11-q13: maternal deletion 70 % No Up to 50 % mental retardation, microcephaly,
no speech, unmotivated laughing,
ataxia, seizures, scoliosisupd(15)pat 1-3 % In case of RT
aberrant methylation ~4 % Yes <1 %
UBE3A point mutations 10-15 % No In familial cases: up
to 50 % in case of
maternal transmission
Precocious puberty
(central precocious
puberty 2; cppb2)
Unknown 614356 15q11.2: MKRN3 point mutations 100 % No In familial cases: up
to 50 % in case of
paternal transmission
Early activation of the hypothalamic-
pituitary-gonadal axis results in
gonadotropin-dependent precocious
puberty
Upd(16)mat Unknown Chromosome 16 upd(16)mat, often
associated with
chromosomal aberrations
Yes <1 % IUGR (40-85 %); heterogeneous, but
no specific or unique symptoms
Pseudohypo-
parathyroidism (PHP1B,
PHP1C, PHP1A)
unknown 603233 20q13: Maternally inherited
deletions causing
aberrant methylation
8.5 % Up to 50 % in case of
maternal transmission
Resistance to PTH and other
hormones; Albright hereditary
osteodystrophy, subcutaneous
ossifications, feeding behaviour
anomalies, abnormal growth
patterns
612462 GNAS isolated epimutations 42.5 % 12.5 % <1 %
103580 upd(20)pat 2.5 % 12.5 % <1 %
maternal and paternal
heterozygous loss of
function mutations in
GNAS coding sequence
46.5 % No Up to 50 % in case of
maternal transmission
Upd(20)mat syndrome unknown Chromosome 20 upd(20)mat No <1 % IUGR, PNGR, feeding difficulties
IUGR intrauterine growth retardation, PNGR postnatal growth retardation
aThis case carries both upd(7)mat and a TS14 epimutation [82], if studied in different tissues
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Table 2 Comparison of the major clinical findings in the known and suggested IDs, showing a broad clinical overlap between the different disorders
Congenital ID TNDM upd(6)mat SRS BWS TS14 KOS14 PWS AS Precocious
puberty
upd(16)mat PHP upd(20)mat
Reference [18] Weba [83] [33] [43] [84] [52] [85] [61] Weba [86] [70]
number of
patients
155 13 20 44 403 51 34 90 61 63 15
ID specific
chromosome
6 6 7 11 11 14 14 15 15 15 16 20 20
clinical
overlapwith
BWS SRS upd(6)mat, TS14,
upd(16)mat,
upd(20)mat
TNDM, KOS14 SRS, PWS BWS TS14 AS infant SRS,
upd(6)mat,
upd(20)mat
SRS,
upd(6)mat,
upd(16)mat
Major clinical
and overlapping
findings
IUGR Yes 53.8 % (7/13) 70 % 82 % 87 % 1 Rare No 77 % (47/61) 100 %
prenatal
overgrowth
Yes 58.8 % (20/34) No Yes
placenta Abnormality: 8 % Abnormality: 35 % Placentomegaly Placentomegaly No
polyhydramion Reported 97 % (33/34) No
PNGR Yes 33.3 % (2/6) 65 % 57 % 79 % 36.6 % (11/30) 63 % No 2 % (1/49) 100 %
overgrowth Yes (6.7 % (2/30) No
organomegaly 43.8 % (153/349) No
Asymmetry 30 % 68 % 33.3 % (126/378 4 % No
macroglossia 44 % (54/123) 94 % (379/403) No 7 %
(3/35)
relative
macrocephaly
90 % 70 % 56 % No 1 case
relative
microcephaly
1 case >80 %
hypotonia 45 % (n = 143) [87] 93 % 88 % <80 % 1 case
abdominal wall
defects
21 % (24/114) 1 case Rare 62.3 % (250/401) Omphalocele:
32.3 % (11(34)
No 1 case
Exomphalos:
56.8 % (142/250)
diastasis recti:
67.6 % (23/34)
glycemic
disorder
TNDM: 100 % Hypoglycemia:
24 %
Hypoglycemia:
19 %; diabetes
type 2 reported
in later life
Hypoglycemia:
43.4 % (162/373)
Hypoglycemia
diabetes type
2 reported in
later life
Diabetes
type 2: 25 %
no
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Table 2 Comparison of the major clinical findings in the known and suggested IDs, showing a broad clinical overlap between the different disorders (Continued)
precocious
puberty
Frequent Frequent Reported 86 % 4 % [88] No 100 %
mental
retardation
Global delay:
65 %
Global delay: 20 % 39 % 100 % 100 % 3 %
speech delay 50 % 39 % No
speech
motor delay 50 % (7/14) 76 % (26/34) 100 %
learning
difficulties
100 % 33 %
behaviour 20 % 9 % 70-90 % 100 % 9 %
feeding
difficulties
90 % 84 % Reported 43 % 78 % >80 % 7 cases
seizures 1 case >80 % 1 case
excessive
sweating
75 % 64 % Increased
sensitivity
to heat
scoliosis 5 % 9 % 23 % 40-80 % [88] <80 % 1 case
adipositas Reported in
later life [21]
yes 67 % <80 %
dysmorphic/
typical facial
gestalt
18 % (21/114) Triangular face 100 % >80 % 14.2 %
(6/49)
Mild
clinodactyly/
finger
abnormalities
8 % (9/116) 45 % 75 % 5 cases
ear abnormalities Low set
posterior
Low set posterior 61.8 % (230/372)
otitis media 20 % 14 % 17.6 % (9/51)
hepatoblastoma Reported Reported
cardiac
anomalities
9 % (10/114) 9 % 5-10 % [39]
aSee http://www.fish.uniklinikum-jena.de/UPD.html (15.06.2015)
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Eggermann et al. Clinical Epigenetics  (2015) 7:123 Page 15 of 18and short stature are long known features of PHP1A, it be-
came only recently apparent that growth and metabolism
are affected in both paternal and maternal (epi)genetic al-
terations of the GNAS locus [65, 66].
Do further imprinting disorders exist?
Despite the gaps in understanding their pathoaetiology
and their clinical heterogeneity, the aforementioned IDs
are meanwhile well established as they are associated
with molecular changes in disease-specific loci. However,
three further clinical entities have been suggested in
which imprinted genes are known or suspected to be in-
volved, and which might become IDs.
Maternal uniparental disomy of chromosome 6
(upd(6)mat)
Maternal UPD of chromosome 6 (upd(6)mat) has been
hypothesized to be associated with intrauterine growth
retardation: among the 13 cases reported so far, 7 re-
vealed a IUGR (http://www.fish.uniklinikum-jena.de/
UPD.html). Indeed, homozygosity of a recessive allele
causing IUGR has been discussed as the pathogenic
mechanism as many patients share an isodisomic region
in 6q16qter. However, not all upd(6)mat carriers pre-
senting IUGR share this region, in one case homozygosity
of a recessive CUL7 has been identified causing 3 M
syndrome, a growth retardation syndrome. However, it
has been postulated that upd(6)mat might be regarded as
a further imprinting disorder [67].
Maternal uniparental disomy of chromosome 16
(upd(16)mat)
Maternal UPD of chromosome 16 (upd(16)mat) is the
most often reported UPD other than upd(15). This is
not surprising since risk of UPD is much higher in chro-
mosomes involved in aneuploidies and trisomy 16 is the
most common autosomal trisomy in human abortions.
Trisomy 16 itself is usually lethal in non-mosaic state in
the fetus, but in trisomy rescue is compatible with life. As
a consequence of UPD formation by trisomy rescue, many
of the reported upd(16)mat cases are associated with tri-
somy 16 mosaicism in the placenta (for review, http://
www.fish.uniklinikum-jena.de/UPD.html). The upd(16)mat
has been suspected to have clinical consequences. How-
ever, the heterogeneity of the birth defects observed sug-
gested that the phenotype might rather be influenced by
placenta insufficiency than by the UPD itself [68]. The pos-
sibility that upd(16)mat is associated with imprinting is dif-
ficult to assess due to the trisomy 16 mosaicism present
in many cases. By an extensive clinical analysis of a
series of mosaic trisomy 16 cases (n = 83) including
upd(16)mat (n = 33), Yong et al. [69] concluded that
upd(16)mat might be associated with more severe
growth retardation in utero and an elevated risk ofmalformation. However, the role of imprinted genes on
chromosome 16 contributing to the phenotype is un-
clear at the moment.
Maternal uniparental disomy of chromosome 20
(upd(20)mat)
Maternal uniparental disomy of chromosome 20
(upd(20)mat) has been reported in 12 patients [70], 3 of
whom also had mosaicism for complete or partial tri-
somy of chromosome 20. All patients with upd(20)mat
had intrauterine and postnatal growth retardation, and
prominent feeding difficulties with failure to thrive
often requiring gastric tube feeding in the first few
years of life. No dysmorphisms or congenital abnormal-
ities or major developmental delay have been reported.
So far, other types of molecular alterations have not yet
been reported, and a candidate region on chromosome
20 has not yet been defined. It is striking that these pa-
tients have not been described to have features reminis-
cent of paternal GNAS loss of function mutations,
although the loss of the paternal GNAS allele (on chromo-
some 20) is associated with pre- and postnatal growth de-
fect and Albright hereditary osteodystrophy [8]. However,
upd(20)mat probably presents a new imprinting disorder
and its identification requires specialized molecular
testing, which should be performed in patients with
early-onset idiopathic isolated growth failure. In par-
ticular patients with a clinical diagnosis of SRS or
TS14, but exclusion of their known molecular distur-
bances, are strong candidates for upd(20)mat as there
appears to be significant phenotypic overlap.
Multi-locus imprinting disturbances and the
“imprinted gene network”
The clinical and molecular overlap between IDs suggests
that there may be causal links between them, either by
shared causes of dysregulation affecting multiple imprinted
genes, or by perturbation of interactions between the prod-
ucts of imprinted genes.
A growing number of ID patients have been reported
to exhibit multilocus imprinting disturbance or MLID
which can vary depending on the tissues studied [22, 71]
(Table 1). Whilst the mechanisms associated with MLID
are currently unknown, they all present with underlying
aberrations in allelic DNA methylation. Indeed, evi-
dence is growing that genomic mutations are involved
in the etiology of MLID; known trans-acting factors
include mutations in the ZFP57, the NLRP2 or the
NLRP7 genes [72–75].
Another hypothesis which explains the clinical and
molecular overlap between the different IDs is the
“imprinted gene network” (IGN) [76]. The existence of
the IGN has been based on the observation of co-
expression of imprinted transcript, as recently reported
Eggermann et al. Clinical Epigenetics  (2015) 7:123 Page 16 of 18for the imprinted transcription factor PLAGL1, the gene
responsible for TNDM [77]. Changes in imprinted gene
abundance occur due to increased transcription from the
active allele in a DNA methylation independent fashion
[78]. Recently, additional gene networks have been de-
scribed including the role of unoccupied insulin (IR) and
insulin-like growth factor 1 receptor (IGF1R) signalling in
the coordinated regulation of multiple imprinted genes as-
sociated with growth and development in mouse [79].
Interestingly this regulation is independent of PLAGL1,
despite this gene being downregulated by more than 80 %
in the IR and IGF1R double knockout cells.
Finally the paternally expressed non-coding RNA IPW
located in the commonly deleted chromosome 15 region
in PWS regulates the levels of maternally expressed tran-
scripts within the imprinted cluster on chromosome 14
[80]. The transcriptional repression of the DLK1-DIO3
locus by IPW is due to altered repressive histone modifi-
cations at the IG-DMR, which is independent of DNA
methylation, via targeted recruitment of the histone meth-
yltransferase G9a. These observations support the reports
of affected individuals with TS14 who display PWS-like
phenotypes [81], enforcing the view that phenotypes asso-
ciated with some IDs may be caused by aberrant expres-
sion of imprinted genes within other imprinted loci.
Conclusion
Recent rapid advances in the molecular and clinical
pathogenesis of IDs have vividly illustrated the complex-
ity of imprinting regulation, its vulnerability to genetic
and epigenetic disturbance and its power as a paradigm
of the interplay between genetics, epigenetics and
phenotype. Identification of new mutational and epimu-
tational pathways offers the potential for more precise
molecular diagnosis and the development of new thera-
peutic regimes as the basis for a more directed and per-
sonalised medicine in IDs. At the same time, study of
IDs may have impact beyond the borders of rare disor-
ders, since they offer clear and tractable paradigms of
the interplay between genetic, epigenetic and environ-
mental variation upon human disorders spanning distur-
bances of growth and metabolism, diabetes and cancer.
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